Results 31 to 40 of about 10,402 (207)

Modeling pegylated liposomal doxorubicin-induced hand-foot syndrome and intestinal mucositis in zebrafish [PDF]

, 2014
Pegylated liposomal doxorubicin (PLD) has been widely used to treat cancer. The adverse effects of PLD noted in clinical practice, especially hand-foot syndrome (HFS), are regarded as unique, and the management methods for them remain limited. This study
Chen YH; Lee YT; Wen CC; Chen YC; Chen YJ
core   +1 more source

Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin

World Journal of Clinical Oncology, 2012
To assess the efficacy and safety of the combination of pegylated liposomal doxorubicin (PLD) and carboplatin in patients with recurrent epithelial ovarian carcinoma (ROC), following disease progression on single agent PLD.An analysis of the medical records of 10 patients with ROC, treated in our institution with a combination of PLD and carboplatin ...
Tal, Grenader, Ora, Rosengarten, Rut, Isacson, Yevgeni, Plotkin, Alberto, Gabizon   +4 more
openaire   +2 more sources

"In vitro" and "in vivo" drug targeting using biotinylated immunoliposomes [PDF]

, 2005
The aim of my thesis was the optimization, characterization and application of a new, innovative drug carrier system which can be used to target pharmaceuticals to diseased tissues and organs.
Schnyder, Anita
core   +1 more source

PEGylated versus Non-PEGylated pH-Sensitive Liposomes: New Insights from a Comparative Antitumor Activity Study

Pharmaceutics, 2022
PEGylated liposomes are largely studied as long-circulating drug delivery systems. Nevertheless, the addition of PEG can result in reduced interactions between liposomes and cells, hindering liposomal internalization into target cells.
Shirleide Santos Nunes, Juliana de Oliveira Silva, Renata Salgado Fernandes, Sued Eustaquio Mendes Miranda, Elaine Amaral Leite, Marcelo Alexandre de Farias, Rodrigo Villares Portugal, Geovanni Dantas Cassali, Danyelle M. Townsend, Mônica Cristina Oliveira, André Luís Branco de Barros   +10 more
doaj   +1 more source

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials [PDF]

, 2010
Background: We conducted a systematic review and meta-analysis to clarify the risk of early and late cardiotoxicity of anthracycline agents in patients treated for breast or ovarian cancer, lymphoma, myeloma or sarcoma.Methods: Randomized controlled ...
Gill Levitt, Smith Lesley A, Cornelius Victoria R, Canney Peter, Levitt, G, Smith, Lesley A., Canney, P, Verrill, Mark, Lesley A Smith, Cornelius, Victoria, Verrill Mark, Plummer, CJ, Verrill, M, Peter Canney, Cornelius, VR, Lesley, A. Smith, Canney, Peter, Plummer, Christopher J., Victoria R Cornelius, Plummer Christopher J, Alison Jones, Smith, LA, Christopher J Plummer, Jones, Alison, Jones Alison, Jones, A, Levitt Gill, Levitt, Gill, Cornelius, Victoria R., Mark Verrill   +29 more
core   +1 more source

Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer

Data in Brief, 2020
The data presented herein are supplementary to our published primary article “A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer”[1].
Bradley J. Monk, Thomas J. Herzog, George Wang, Spyros Triantos, Scott Maul, Roland Knoblauch, Tracy McGowan, Waleed S.W. Shalaby, Robert L. Coleman   +8 more
doaj   +1 more source

Pegylated-liposomal Doxorubicin-induced Glomerular Thrombotic Microangiopathy. [PDF]

Intern Med
Pegylated liposomal doxorubicin (PLD) has emerged as a recent innovation within the realm of antineoplastic agents, distinguished by its incorporation of doxorubicin within the liposomal bilayer. Given the low risk of cardiotoxicity, the clinical use of PLD has been expanding.
Yokoyama S, Kakeshita K, Imamura T, Shima T, Fujioka H, Yamazaki H, Koike T, Kinugawa K.   +7 more
europepmc   +3 more sources

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer [PDF]

Cochrane Database of Systematic Reviews, 2013
Ovarian cancer is the eighth most common cancer in women and it is usually diagnosed at an advanced stage. The majority of ovarian tumours are epithelial in origin. Women with relapsed epithelial ovarian cancer (EOC) often have a reduced performance status with a limited life expectancy, therefore maintaining quality of life with effective symptom ...
Theresa A, Lawrie, Andrew, Bryant, Alison, Cameron, Emma, Gray, Jo, Morrison   +4 more
openaire   +2 more sources

Harnessing Nanomedicine to Potentiate the Chemo-Immunotherapeutic Effects of Doxorubicin and Alendronate Co-Encapsulated in Pegylated Liposomes

Pharmaceutics, 2023
Encapsulation of Doxorubicin (Dox), a potent cytotoxic agent and immunogenic cell death inducer, in pegylated (Stealth) liposomes, is well known to have major pharmacologic advantages over treatment with free Dox.
Alberto Gabizon, Hilary Shmeeda, Benjamin Draper, Ana Parente-Pereira, John Maher, Amaia Carrascal-Miniño, Rafael T. M. de Rosales, Ninh M. La-Beck   +7 more
doaj   +1 more source

Paclitaxel and pegylated‐liposomal doxorubicin are both active in angiosarcoma [PDF]

Cancer, 2005
AbstractBACKGROUNDPaclitaxel has unique activity in angiosarcomas of the face and scalp, but its activity in angiosarcomas originating at other sites is less well defined. Paclitaxel and pegylated‐liposomal doxorubicin (PLD) are highly effective in Kaposi sarcoma (KS).
Keith M, Skubitz, Philip A, Haddad
openaire   +2 more sources